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Summary Polyalkylcyanoacrylate (PACA) nanoparticles loaded with doxorubicin allowed multidrug resistance to be overcome in vitro.
However, increased cytotoxicity is not always correlated with an increased level of intracellular drug. Although we have previously shown that
PACA nanoparticles are not endocytosed by tumour cells, we report here that a direct interaction between nanoparticles and cells is a
necessary requirement for overcoming resistance. In addition, the results showed that the degradation products of PACA (mainly
polycyanoacrylic acid) in the presence of doxorubicin are able to increase both accumulation and cytotoxicity, thus suggesting the formation
of a doxorubicin-polycyanoacrylic acid ion pair. It is therefore concluded that resistance is overcome as a result of both the adsorption of
nanoparticles to the cell surface and increased doxorubicin diffusion by the accumulation of an ion pair at the plasma membrane.
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During the past few years, much attention has been given to the
mechanisms by which cancer cells become resistant to doxo-
rubicin (Dox). Most of the studies have focused on the P-glyco-
protein (P-gp)-dependent mechanism of the (MDR) phenotype. It
has been established that P-gp is a membrane glycoprotein of
about 170 kDa that is thought to expel drugs from the intracellular
to the extracellular medium, via an ATP-dependent mechanism
(Gottesman and Pastan, 1993). Until now, this protein has been
supposed to be a drug transporter (Gottesman and Pastan, 1993), a
flippase (Gottesman and Pastan, 1988) and an ATP channel
(Abraham et al, 1993). Moreover, it has recently been established
that P-gp expression can alter both intracellular pH and the trans-
membrane electrical potential, which can affect cationic drug
accumulation by resistant cells (Roepe et al, 1993).
Several strategies have been investigated to overcome MDR.
Among them, chemical modifications of drugs (Tapiero et al,
1986), co-administration of chemosensitizing compounds, gener-
ally acting as P-gp inhibitors (Kellen, 1993), and the use of drug
carriers such as microspheres, liposomes or nanoparticles can be
mentioned. As far as polymeric nanoparticles are concerned,
Cuvier et al (1992) and Nemati et al (1994) have shown that Dox-
loaded nanoparticles ofpolyalkylcyanoacrylate (NS-Dox) are able
to bypass multidrug resistance in vitro. Furthermore, preliminary
in vivo experiments have given very promising results (Cuvier et
al, 1992). In a previous work, we found that the reversion of the
resistance of the leukaemic cell line P388/ADR by NS-Dox
composed of polyisobutylcyanoacrylate (PIBCA) was related to
an increased accumulation ofdrug by the cells (Colin de Verdiere
et al, 1994). However, the exact mechanism by which these
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nanoparticles overcame resistance ofcells in culture was not clear.
In order to obtain more information, further studies have been
carried out with nanoparticles composed of polyisohexylcyano-
acrylate (PIHCA), described in this paper. In contrast to PIBCA
nanoparticles, with PIHCA nanoparticles no increase in drug
accumulation was found. Similar results have been described by
Bogush et al (1995). The aim ofthe present study was to determine
how two such very similar polymer nanoparticles overcome the
resistance of cells with two completely different effects on the
drug accumulation.
MATERIALS AND METHODS
Cell line and culture
P388 (sensitive cells) and P388/ADR (resistant cell line) were
kindly supplied by the Institut de Recherche sur le Cancer (IRSC,
France). They were grown in suspension, in RPMI-1640 medium
(Gibco, France), supplemented with 10% fetal calf serum (Gibco,
France), penicillin-streptomycin (Eurobio, France) and 3 nM 2-
mercaptoethanol (Sigma, USA).
Chemicals
Free Dox (Adriblastin) was obtained from Farmitalia (Carlo Erba,
Italy). The monomer isohexylcyanoacrylate (IHCA) was kindly
supplied by SOPAR (Belgium). The monomer isobutylcyano-
acrylate (IBCA) was obtained from Sigma. All other chemicals
were obtained commercially and were ofanalytical grade.
Preparation of nanoparticles
Nanoparticles were prepared as described previously (Colin de
Verdiere et al, 1994). Typically, 66.5 mg of monomer (IBCA or
IHCA) was dropped under mechanical stirring into 6.5 ml of
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Figure 1 In vitro Dox release from NS-Dox PIBCA (0) and NS-Dox PIHCA
(U) as a function of incubation time in cell culture medium. The concentration
was 2000 ng ml-'
medium containing 5 mg ofdoxorubicin, 5% glucose, 1% dextran
70 and 0.5% citric acid. After a 24-h (IHCA) or a 6-h (IBCA)
polymerization, nanoparticles were obtained and lyophilized.
Polymerization times were chosen with respect to the polymeriza-
tion rate ofthe monomer, which increases as the alkyl chain length
shortens. The final characteristics of the nanoparticles obtained in
terms ofparticle size or average molecular weight were similar for
PIHCA and PIBCA nanoparticles. The percentage of doxorubicin
associated with the nanoparticles was 95% after resuspension in
distilled water. The size of the nanoparticles was determined by
quasielastic light scattering in a Nanosizer N4MD (Coultronics,
France) and was 186 ± 31 nm for NS-Dox PIBCA and
243 ± 15 nm for NS-Dox PIHCA. Non-loaded nanoparticles
(NS-PIBCA and NS-PIHCA) were obtained by the same method,
in the absence ofdoxorubicin in the polymerization medium.
In vitro release of Dox
The rate ofDox release from NS-Dox PIBCA and NS-Dox PIHCA
was measured in vitro. The drug-loaded nanoparticles were incu-
bated in the culture medium at a Dox concentration of 2 jig ml-' at
37°C in a humidified atmosphere containing 5% carbon dioxide.
Free Dox was incubated under the same conditions as a control.
Samples were taken after various incubation periods and nanoparti-
cles were separated from the released drug by ultrafiltration on a
polysulphone membrane (300 000 Da molecular weight cut-off;
Millipore, France) at 2000g for 5 min. The filtrate was assayed by
HPLC as described in Colin de Verdi&re et al, 1994.
Studies of drug accumulation by cells in culture
Cells were seeded at adensity of5 x 10 cells ml-'. After 22 h, Dox,
NS-Dox PIBCA or NS-Dox PIHCA were added to the culture
medium in order to reach a final concentration of 0.1jIg ml-' for
sensitive P388 cells and 2 jig ml-' for resistant P388/ADR cells.
In some experiments, using P388/ADR cells only, we also
measured the accumulation of doxorubicin after preincubation of
the nanoparticles (with or without loaded drug) in cell culture
medium (NS-PIBCA, NS-Dox PIBCA, NS-Dox PIHCA and Dox
as control). This preincubation led to the more or less complete
bioerosion of the nanoparticles, depending on the duration for
which it was performed. Preincubation was carried out at a Dox
concentration of 2 ,ug ml-', corresponding to a polymer concentra-
tion of 26 ,ug ml-' for different periods of time (1 h for NS-Dox
PIBCA and NS-PIBCA and 3 h or overnight for NS-Dox PIHCA).
Thereafter, the contents of wells, which had been previously
seeded with cells, were centrifuged and the supernatants were
discarded. The cell pellets were then resuspended in medium
containing the preincubated nanoparticles. After varying periods
of incubation with the drug, cell-associated Dox was determined
as described by Colin de Verdiere et al (1994).
Inhibition of cell growth
The following were assessed for theirability to inhibit cell growth:
free Dox, Dox-loaded nanoparticles made of PIHCA (NS-Dox
PIHCA) or PIBCA (NS-Dox PIBCA), unloaded nanoparticles
(NS) and a mixture of free Dox and unloaded nanoparticles
(NS+Dox). Cells (P388 and P388/ADR) were incubated for48 h at
5 x 104 cells ml-' with various concentrations of the drug. The
resulting cell number was determined in a model ZM Coulter
counter (Coultronics, France). Some experiments were carried out
in special wells (Costar, France) consisting of two compartments
separated by a porous membrane (polycarbonate, pore size
0.1 ,Im). Cells were seeded in the lower compartment and the drug
samples were added to the upper part, leading to the absence of
direct contact between the cells and the nanoparticles. Lastly, in
some experiments, we also measured the inhibition of cell growth
after preincubation ofthe nanoparticles (drug-loaded or not) in the
cell culture medium as described above.
All the experiments ofinhibition ofcell growth were carried out
on both sensitive and resistant P388 cells. For each one of the
figures included in the results section, the error bars correspond to
the intraexperimental variations (mean of three different wells).
Each experiment was repeated three times with similar results.
Spectroscopic analysis of doxorubicin
The existence of a complex between Dox and poly(cyanoacrylic
acid) was sought using FT-IR and FT-Raman spectroscopy.
Poly(cyanoacrylic acid) was obtained as follows: NS-PIBCA were
washed three times with distilled water and ultracentrifuged. Then,
0.5 ml of 0.2 N sodium hydroxide was added to 1 ml of a suspen-
sion containing 10 mg ml-' NS-PIBCA. Forty-eight hours later, the
pH was adjusted to 7.4 with 1 N hydrochloric acid. An aliquot
(145 jl) ofan aqueous Dox solution (5 mg ml-') was then added to
the hydrolysed polymer: a red precipitate appeared instantanously.
After centrifugation at 15 400 g (Sigma 2K15), the pellet was
resuspended in 100 jil ofdistilled water and lyophilized.
The dried solid was analysed by FT-IR (Nicolet SX60) and FT-
Raman (Perkin Elmer System 2000, X = 1060 nm, YAG laser).
RESULTS
In vitro release studies
As shown in Figure 1, Dox release from nanoparticles in culture
medium was much faster in the case of PIBCA nanoparticles than
in the case of PIHCA ones. Drug release from PIBCA started
immediately and was complete within 1 h. In the case of PIHCA,
the release displayed a biphasic character: no significant release
occurred within the first hour, and complete release was only
observed after 400mM.
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Drug accumulation in cells in culture
Cell accumulation experiments with NS-Dox PIBCA and
NS-Dox PIHCA
As described in Materials and methods, cells were incubated with
Dox, NS-Dox PIBCA and NS-Dox PIHCA. In the case of sensitive
P388 cells, incubated in the presence of 0.1 ,Ig ml-1 doxorubicin,
the drug accumulation level was the same whatever the drug formu-
lation (free Dox or NS-Dox). Similar results have already been
published (Colin de Verdiere et al, 1994). When P388/ADR cells
were incubated with Dox at a concentration of 2 jig ml-l, the accu-
mulation quickly reached a steady state, corresponding to 20 ng
doxorubicin per million cells (Figure 2A). When incubated with
PIBCA nanoparticles, doxorubicin accumulation was increased to
300 ng per million cells, which represents about 15 times the level
obtained after a 6-h incubation with free Dox.
Surprisingly, when PIHCA nanoparticles were used, drug accu-
mulation was very low (Figure 2B) and not significantly different
from that observed after incubation with free Dox. This result is
inconsistent with the data reported in previous cytotoxicity experi-
ments, showing that NS-Dox PIBCA and NS-Dox PIHCA were
equally cytotoxic (Nemati et al, 1994). This comparison suggests
that cytotoxic effects ofnanoparticles are not a direct consequence
ofdrug accumulation within cells.
British Journal ofCancer (1997) 76(2), 198-205
B
11
0
c
1-
.5
U
CL
cm
S
lime (min)
.3001
a
c
0 E 200
0
CM ioo.
n
.I
5Dox
0NS-PIBCA deg + Dox
0 160 .2Q0 300
lime (min)
E
(a
0,
C.
c
lime (min)
p .J.
0 Cancer Research Campaign 1997Reversion ofMDR with PACA nanoparticles 201
A
With contact NSlcells (a) WithoutcontactNS/cells (b)
._
I
6.
5-
8
E
c
I:
NS-Dox PICA
N*'SPIHCA
10D 100 1000
Doxorubioin conitentration (ng-mFl)
Wih oontact NSolIcs (a)
100~
80~
80
40-
*20
. 10000
NPIox CA
.. .... .D..
.*
'.n.10. 10O.. ., 1000.
*Doxorubicin concetatio (ng mlH)
.Wiho.ut oontactNS/cells (b).
10 1.0.0 iooO
'.I
w.
II-b
E
C W.
if.
w00 10000,
I
80-
0.
.20--~
. 04.s
0
.
Doxonrbidn connatior (ngmi-)
N64 RSPxlIHCA,
* -NS-PIH * ...
:10: -: 1;Q0 1000
D -xorubicinconcentration(g m.) Doxorubldnconw 4kamu" Fn m1
Figure 3 Cytotoxicity against P388 (A) and P388/ADR (B) of PIHCA nanoparticles in a two-compartment well (a) without the presence of the separating
membrane and (b) in the presence of the separating membrane
Cell accumulation experiments with preincubated
nanoparticles (NS-Dox PIBCA and NS-Dox PIHCA)
When NS-Dox PIBCA were preincubated for 1 h in the culture
medium before incubation with the cells, the accumulation ofDox
did not differ markedly from the accumulation obtained with non-
degraded NS-Dox PIBCA (Figure 2C). After a 6 h incubation, no
equilibrium was reached and the amount of drug associated with
the cells was 220 ng per million cells (i.e. 3.6 times the level
obtained after an incubation with free Dox).
In cell accumulation experiments with the degradation products
of NS-Dox PIHCA, the amount of drug associated with the cells
depended on the time ofpreincubation ofthe nanoparticles (Figure
2E): after a period of incubation of 3 h, which corresponds to 50%
release of the drug in the cell culture medium (see Figure 1), cell
accumulation of doxorubicin was not significantly increased
compared with intact NS-Dox PIHCA.
In contrast, after complete release ofthe drug from the nanopar-
ticles, achieved by an overnight preincubation ofNS-Dox PIHCA,
the accumulation of the drug by the cells was significantly
increased and reached a value of 130 ng per million ofcells after a
6-h incubation time. This represented approximately 2.6 times the
Dox cell accumulation value ofthe control (Dox) and 3.2 times the
accumulation level of intact NS-Dox PIHCA.
Cell accumulation experiment with a mixture of
preincubated NS-PIBCA and Dox
When P388/ADR cells were incubated with a mixture of the
degradation products of NS-PIBCA and free Dox, a considerable
increase in the accumulation ofdrug by the cells was observed, as
compared to the free Dox (Figure 2D). After a 6 h incubation,
accumulation of the drug reached approximatively 450 ng per
million cells, which is close to 4.5 times the value of the control
(100 ng per million cells for Dox).
Inhibition of cell growth
Two-compartment well experiments
Cells were seeded in the lower compartment ofthe wells and could
be separated from the drug compartment by a mobile porous
membrane. When the experiment was carried out with sensitive
British Journal of Cancer (1997) 76(2), 198-205
100-
80-
80-
40
20-
.e
8;
.c
B
,r n .w.w -
.1QQ1m
o 8
'B
2 E
.8 'I -U
MC
100
80-
BO'
40Q-
20'
0 Dox
* NS-DoxPIHCA
* NSPIHCA
_ . . -
1.0000
-n. W l _- _ _- Irm -----U W.M. n .I _- .--.. _-- _u - ---. S
0 Cancer Research Campaign 1997202 AC de Verdiere et al
A
0
a)
0
U1) 0~
120
1)00
80
..,W.. *40S
....2
,207
Degradation time (h)
Figure 4 Cytotoxicity against P388/ADR of PIHCA and PIBCA nanoparticles
(non-loaded and doxorubicin-loaded) as a function of the time of
preincubation of the nanospheres before their addition to the cells. Dox
concentration was 200 ng ml-1
P388 cells (Figure 3A), it was observed that Dox and NS-Dox
(NS-Dox PIHCA in the figure) were equally cytotoxic in the
absence (Figure 3Aa) or in the presence (Figure 3Ab) of the
membrane. The only difference was due to a partial adsorption of
doxorubicin onto the membrane, leading to higherIC50 in the pres-
ence of the separating membrane (Figure 3Ab as compared with
Figure 3Aa). It was also noted that unloaded nanospheres (NS-
PIHCA) appeared to be less cytotoxic towards P388 cells when
direct contact between nanoparticles and cells was inhibited by the
porous membrane. This observation has already been discussed
elsewhere (Lherm et al, 1992) and was attributed to a membrane
cytotoxic effect of the degradation products of the polymer
released and concentrated close to the cell surface when nanoparti-
cles were adsorbed onto the cells.
As far as P388/ADR cells were concerned, when they were not
in direct contact with the drug (Figure 3Bb), NS-Dox PIHCA
appeared to be as cytotoxic as the free drug, and non-loaded
nanoparticles appeared non-cytotoxic at the doses investigated.
Thus, the presence of the separating membrane led to a sharp
decrease in the cytotoxicity ofthe nanoparticles (as compared with
studies performed in the absence ofthe membrane; Figure 3Ba).
Experiments performed with preincubated nanoparticles
Nanoparticles were incubated in the culture medium before addi-
tion to the cells. Figure 4 shows that, in the case of P388/ADR
cells, the particle cytotoxicity was decreased when NS-Dox was
preincubated in the culture medium. Cytotoxicity was completely
abolished after a 2-h incubation for PIBCA and after a 6-h incuba-
tion for PIHCA. These time periods correspond to the complete
bioerosion of the particles, PIBCA being degraded much faster
than PIHCA (see Figure 1).
A final set of experiments was carried out with nanoparticles
preincubated for a time sufficient to allow complete degradation of
nanoparticles. In the case of P388 sensitive cells, there was no
difference in cytotoxicity between Dox, NS-Dox or preincubated
NS-Dox (Figure 5A), whereas preincubated unloaded nanospheres
were less cytotoxic than original non-loaded nanospheres. In the
case of P388/ADR cells, the results were more complex. The
totally bioeroded NS-Dox particles (NS-Dox preincub) were still
more cytotoxic than the free drug (the IC90 being 500 ng ml-' and
1500 ng ml respectively) although this cytotoxic effect was lower
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Figure 5 Cytotoxicity against P388 (A) P388/ADR (B) and of free Dox, NS-
Dox PIBCA, NS-PIBCA and completely bioeroded nanoparticles (NS-
preincub, NS-Dox preincub and a mixture of free Dox and NS-preincub)
than in the presence of intact particles (IC50 around 70 ng ml-')
(Figure SB). It was even shown that a mixture of Dox with the
preincubated polymer was more cytotoxic than would have been
expected from the simple addition of the cytotoxic effects of the
free drug and of the preincubated polymer (Figure SB). Indeed, at
a Dox concentration of 500 ng ml', the mixture NS preincub +
Dox resulted in 50% cytotoxicity, whereas NS preincub alone and
Dox alone led to 80% and 85% ofthe control respectively.
Spectroscopic analyses
As shown in Figure 6, the Fourier transform (FT) Raman spectrum
ofthe red precipitate obtained when hydrolysed PIBCA was added
to a Dox solution, appeared to be the superposition ofthose ofDox
and of the hydrolysed polymer. Ofparticular interest are the bands
observed from 1800 cm-' to 200 cm-', mainly attributed to doxo-
rubicin, and the band at 2250 cm-' corresponding to CN groups, a
specific function ofpolycyanoacrylate. Fourier transform infrared
spectroscopy gave similar information, although the spectra were
less clear because of the lower intensity of the band at 2250 cm-'.
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Figure 6 FT-Raman spectra of hydrolysed NS PIBCA (A), Dox (B), and the
precipitate obtained after mixing of Dox and hydrolysed NS PIBCA (C)
These observations allowed the identification of both polycyano-
acrylic acid and Dox in the precipitate.
DISCUSSION
Dox-loaded nanoparticules composed of polyalkylcyanoacrylate
have been shown to reverse multidrug resistance for various cell
lines such as SKOV3, B16, K562, P388, MCF7, C6 and DCF3 in
vitro (Bennis et al, 1993; Cuvier et al, 1992; Nemati et al, 1994).
The supposed mechanism was that the nanoparticle-associated
drug would enter the cells by an endocytotic pathway, thus
bypassing the P-gp-dependent efflux. This would lead to an
increased intracellular drug concentration that in turn would
increase the drug cytotoxicity.
Preliminary accumulation studies (Colin de Verdiere et al,
1994) supported this hypothesis, as it was found that incubation of
P388/ADR cells with NS-Dox PIBCA led to an increased accumu-
lation of Dox compared with the free Dox. However, it was also
shown that the endocytotic process could not, by itself, be respon-
sible for this (Colin de Verdiere et al, 1994). We then put forward
the hypothesis that some nanoparticles could adhere to the cell
membrane, thus creating a very high local concentration of
doxorubicin. The increased concentration gradient could have
improved the diffusion of the drug from the extracellular medium
to the intracellular medium, thus leading to a probable saturation
of Pgp efflux.
In the present study, a comparison of two types of polyalkyl-
cyanoacrylate gave additional information. In contrast to the
results obtained with NS-Dox PIBCA, incubation of resistant cells
with NS-Dox PIHCA did not increase drug accumulation
compared with the free form. On the contrary, accumulation was
slightly diminished. This observation was surprising, because
NS-Dox PIBCA and NS-Dox PIHCA were found to be equally
cytotoxic (Nemati et al, 1994). However, as nanoparticles were not
endocytosed by the P388/ADR cells, the only drug available to the
cells was the drug released by the nanoparticles. Compared with
NS-Dox PIBCA, the release ofdoxorubicin from NS-Dox PIHCA
was slower and was supposed to be the limiting process in the
intracellular accumulation of the drug. These first results are in
agreement with the hypothesis that cell membrane-adsorbed
nanoparticles would deliver their encapsulated material to the cell.
On the other hand, after preincubation of NS-Dox PIHCA, it
was observed that the more the nanoparticles were degraded, the
more the intracellular drug level was increased. Moreover, when
preincubated NS-PIBCA and Dox was incubated together it was
observed that the drug accumulation in the cells was also greatly
increased. These data confirmed that doxorubicin release from
nanoparticles was really a limiting step, because once the whole
Dox had been released, PIHCA and PIBCA behaved similarly.
However, in every experiment carried out with preincubated
nanoparticles, the intracellular drug level (ranging from 1 to 4.5
times the control level) never reached the accumulation reported
with intact NS-Dox PIBCA (15 times the cell accumulation of the
control), which is in favour of the role of a local drug concentra-
tion gradient close to the cell membrane. Finally, these observa-
tions suggest that adhesion of the nanoparticles onto the plasma
membrane, thus promoting a drug concentration gradient, could be
a favourable parameter for drug entering the cells. Nevertheless,
the degradation products of nanoparticles also seem to contribute
to an improvement in drug accumulation.
The growth inhibition studies carried out in parallel clearly
showed that the integrity of the particulate form was an important
parameter for the observation of the reversion of MDR. Indeed,
when the particulate form was lost, or when the contact between
the nanoparticles and the cells was inhibited, NS-Dox cytotoxicity
against P388/ADR was markedly decreased and reversion of the
resistance could no longer be observed. It would be expected that
preincubation of NS-Dox would lead to free Dox mixed with
soluble degradation products ofPACA. However, cytotoxicity was
greater than expected from a simple additive effect between free
Dox on one hand, and preincubated drug-unloaded nanospheres on
the other hand. Thus, as suggested from the results ofcell accumu-
lation studies, it seems likely that Dox and nanoparticle degrada-
tion products exerted a synergistic effect. Similar results,
described in the case of liposomes, were interpreted as resulting
from a direct inhibitory effect on P-gp ofphospholipids (Thierry et
al, 1992). Such a hypothesis must be discarded in the case of
polyalkylcyanoacrylate nanoparticles, as the results of Hu et al
(1996) clearly showed the absence of interaction between P-gp
and the degradation products ofthe nanoparticles.
How then should the synergistic effect of Dox and the soluble
degradation products of PACA be interpreted?
In an aqueous medium, and especially in biological fluids, the
degradation of PACA nanoparticles is thought to result from solu-
bilization of the polymer because of hydrolysis of lateral ester
bonds (Leonard et al, 1966). Indeed, such hydrolysis leads to the
appearance of carboxylic groups. At neutral pH, these groups are
mainly present under their ionized form (COO-), and, in this way,
are able to solubilize the whole chain. The solubilization of the
polymer would lead to the release of the encapsulated drug into the
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medium. As a consequence, the release of the drug implies the
presence ofpolycyanoacrylic acid in the medium, as shown below.
esterases
HO-CH2-4LC.oIHK*. - HO-CH2--C--H + 3 ROH
Polyalkylcyanoacrylate Poly (cyanoacrylic acid)
As approximately 90% of doxorubicin (pK 8.4) is positively
charged in the culture medium, ionized doxorubicin may interact
with the polycyanoacrylic acid to form a neutral complex, a so-
called ion pair. This hypothesis is supported by the following
observations:
1. Doxorubicin is able to form ion pairs with various anions,
which leads to a modified permeability ofthe anthracycline
across membranes (Trotta et al, 1988).
2. In the culture medium, the number ofcarboxylic groups
resulting from hydrolysis ofpolyalkylcyanoacrylate is
theoretically much higher than the number of molecules of
Dox (about 40 carboxylic groups for 1 doxorubicin molecule).
3. Such an ion pair between Dox and polycyanoacrylic acid could
be stabilized in the plasma membrane, as Gunn (1978) and Lee
et al (1987) have demonstrated that the formation of an ion
pair and its stability is favoured in a medium with a low
dielectric constant, which is the case for plasma membranes.
The increased intracellular accumulation of doxorubicin is
consistent with the hypothesis of the formation of a complex
between Dox and polycyanoacrylic acid. Indeed, Dox molecules
are thought to enter the cell by passive diffusion ofthe non-ionized
form through the lipid bilayer (Frezard and Gamier, 1991). In
contrast, the protonated form would interact with the phospholipid
headgroups of the lipid bilayer by an electrostatic interaction
(Manella and Wang, 1989), thus lowering the drug membrane
permeability. As a consequence, any substitution or modification
ofthis molecule susceptible to neutralize its cationic charge would
also improve its diffusion through the plasma membrane. In such a
way, Priebe et al (1993) have shown that the substitution of the
amino group of the sugar moeity of the Dox by hydrogen,
improved both its cytotoxicity and accumulation by the cells.
One may argue that neither doxorubicin uptake nor its cytotoxi-
city was increased by polycyanoacrylic acid in the case of sensi-
tive P388 cells. Thus, the question of the origin of the particular
effect of PACA nanoparticles on resistant cells remains. Many
authors have demonstrated that the transmembrane electrical
potential of resistant cells, including P388, is altered (Lampidis et
al, 1985; Gupta et al, 1986; Vayuvegula et al, 1988), leading, by
itself, to a lower intracellular accumulation of cationic drugs
(Ramu et al, 1991). Masking the positive charge of doxorubicin
would then have more consequence for the resistant cells than for
sensitive ones whose membrane potential is not so great a barrier
to the diffusion ofcationic drugs.
The formation of such an ion pair complex is currently under
investigation. Up to now, it has been observed that doxorubicin
precipitates when the degradation products of the polymer are
added to a doxorubicin solution. Spectroscopic analyses clearly
showed that doxorubicin and polycyanoacrylic acid were both
present in this precipitate. There is a high probability that such a
complex exists as an ion-pair as the absence of electric charge and
the increased lipophilicity of ion pairs generally lead to a
compound with decreased solubility that tends to precipitate in
aqueous media.
In conclusion, the mechanism of action we suggest to explain
the reversion of MDR resistance with polycyanoacrylate nanopar-
ticles is that nanoparticles adsorb to the surface of tumour cells,
releasing their encapsulated drug close to the membrane and thus
creating a high local gradient of concentration. At the same time,
nanoparticles degrade and release, among other compounds, poly-
cyanoacrylic acid. As it is probably able to interact with Dox,
polycyanoacrylic acid may contribute to improving the cellular
accumulation of Dox by overcoming the transmembrane electrical
potential. However, it is not out of the question that polycyano-
acrylic acid itself interacts with the plasma membrane in such a
way that Dox accumulation is increased, for example by
increasing the membrane fluidity or by altering transmembrane
electrochemical gradients (Roepe et al, 1994). Such a hypothesis
has already been suggested in the case of liposomes (Warren et al,
1992) and has even been proposed very recently by Dujeda with
respect to surfactants (Dujeda et al, 1995), and also with respect to
reversing agents such as verapamil (Vayuvegula et al, 1988;
Roepe, 1992).
In any case, the mechanism by which resistance is overcome by
PACA nanoparticles appears much more related to the properties
of resistant cell membrane (permeability to doxorubicin, fluidity),
than to a direct interaction with P-gp.
Finally, the question of the in vivo efficacy of doxorubicin-
loaded nanoparticles deserves to be discussed. In fact, when
injected intravenously, nanoparticles are taken up by the liver after
only a few minutes because of the opsonization process (Juliano,
1988). In addition, their size gives them no chance to diffuse
through the endothelium wall. Consequently, any solid tumour,
transplanted subcutaneously for example, cannot be relevant for
testing the in vivo efficacy of nanoparticles in overcoming
multidrug resistance. We and others (Cuvier et al, 1992), published
preliminary results on a resistant P388 model growing as an
ascites, in which nanoparticles were also injected IP. The results
were very encouraging, but it may be considered that such experi-
ments in vivo were too close to in vitro tests as tumour cells and
nanoparticles were injected into the same compartment. For this
reason, we are now considering the development of a liver
metastasis model of MDR M5076 cells.
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